Description
ADAFERIN ™ is indicated for the topical treatment of acne vulgaris with a predominance of comedones, papules and pustules.
It is especially recommended for facial acne and when the chest and back are affected.
Studies carried out in humans have shown that the topical application of ADAFERIN is effective in reducing inflammatory and non-inflammatory acne lesions (comedones, papules and pustules).
ADAFERIN is a retinoid analogue, which has been shown to have anti-inflammatory properties in both in vivo and in vitro inflammation models; It is stable in the presence of oxygen, light and is not chemically reactive. It binds to specific nuclear receptors for retinoic acid, like tretinoin, but unlike tretinoin, it does not bind to cytosolic receptor binding proteins.
In the rhino mouse model, the comedolytic activity of ADAFERIN was verified, as well as its effects on the abnormal processes of keratinization and epidermal differentiation, both processes being part of the pathogenesis of acne vulgaris.
The mechanism of action of ADAFERIN consists of the normalization of the differentiation of follicular epithelial cells, resulting in a decrease in the formation of microcomedones.
Furthermore, ADAFERIN™ has been proven to be superior to other topical retinoids in standard anti-inflammatory studies, both in vivo and in vitro, inhibiting the chemotactic and chemokinetic responses of human polymorphonuclear leukocytes, as well as the metabolism of inflammatory mediators through lipid acid oxidation. arachidonic.
This profile suggests that the cell-mediated inflammatory component of acne can be modified by the action of ADAFERIN.
The level of absorption of ADAFERIN at the percutaneous level is low; clinical studies have reported that no quantifiable levels were detected in plasma.
The metabolism of ADAFERIN has been identified as a process consisting of O-demethylation, hydroxylation and conjugation.
Reviews
There are no reviews yet.